☆ 4.6 Article

A Scalable Synthesis of Roxadustat (FG-4592)

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Biochemical Research Methods

Annual banned-substance review: Analytical approaches in human sports drug testing 2019/2020

Mario Thevis et al.

Summary: Analytical chemistry-based research in sports drug testing has made significant advancements over the past few decades, contributing positively to anti-doping programs and data interpretation. These outcomes have proven invaluable for routine doping controls during the global health crisis.

DRUG TESTING AND ANALYSIS (2021)

添加到收藏夹

Review Urology & Nephrology

The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review

Suhui Qie et al.

Summary: Roxadustat shows significant efficacy in treating anemia in kidney disease patients by increasing hemoglobin levels and improving iron metabolism markers without increasing adverse events. However, more randomized controlled trials are needed to confirm its long-term safety and effectiveness due to study limitations.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2021)

添加到收藏夹

Review Oncology

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options

Russell Lewis et al.

Summary: For patients with LR-MDS, the goal is to alleviate symptoms and reduce transfusion burden associated with anemia. In addition to traditional treatments like supportive transfusions and ESAs, there are other therapeutic options available, such as luspatercept and lenalidomide, with novel agents like imetelstat and roxadustat in development.

CANCER MANAGEMENT AND RESEARCH (2021)

添加到收藏夹

Article Urology & Nephrology

被撤回的出版物: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis (Retracted article. See vol. 7, pg. 665, 2022)

Robert Provenzano et al.

Summary: The study showed that roxadustat was at least as effective as epoetin alfa in patients new to dialysis, with a lower risk of major adverse cardiovascular events and MACE+ in the roxadustat group compared to the epoetin alfa group.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Review Urology & Nephrology

Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia

Xiaofan Hu et al.

Summary: HIF-PHI is a novel therapeutic agent developed to treat anemia in CKD patients by boosting EPO production, enhancing iron utilization, and suppressing hepcidin production. Clinical trials have shown promising results in improving anemia in both nondialysis and dialysis patients. HIF-PHI may also ameliorate lipid metabolism and improve patient compliance with its oral form, making it a potential alternative for anemia correction in CKD patients.

KIDNEY DISEASES (2021)

添加到收藏夹

Article Biochemical Research Methods

Identification of Hypoxia-inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control

Binoy Mathew et al.

Summary: The study on the most popular HIF stabilizer roxadustat and its metabolites in thoroughbred horse urine after oral administration confirmed its effectiveness in treating anemia resulting from chronic kidney disease and provided important evidence for doping control analysis.

DRUG TESTING AND ANALYSIS (2021)

添加到收藏夹

Article Urology & Nephrology

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

Steven Fishbane et al.

Summary: Roxadustat effectively increased hemoglobin levels and reduced the risk of red blood cell transfusion in non-dialysis-dependent CKD patients, with an adverse event profile similar to that of placebo.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Review Environmental Sciences

Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?

Wladyslaw Grzeszczak et al.

Summary: In patients with chronic kidney disease (CKD), anemia develops gradually due to factors like inadequate synthesis of erythropoietin by the kidneys and iron disorders. Current treatments involve iron supplements, erythropoiesis stimulants, and studies are being done on orally administered erythropoiesis drugs, with roxadustat being a promising option.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

添加到收藏夹

Review Chemistry, Applied

Dimethyl Sulfoxide: Yesterday's Solvent, Today's Reagent

Zahra Tashrifi et al.

ADVANCED SYNTHESIS & CATALYSIS (2020)

添加到收藏夹

Review Chemistry, Applied

Potential Explosion Hazards Associated with the Autocatalytic Thermal Decomposition of Dimethyl Sulfoxide and Its Mixtures

Qiang Yang et al.

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis

Junduo Liu et al.

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Review Urology & Nephrology

Treatment of Renal Anemia with Roxadustat: Advantages and Achievement

Li Zuo-Lin et al.

KIDNEY DISEASES (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Roxadustat: First Global Approval

Sohita Dhillon

DRUGS (2019)

添加到收藏夹

Article Chemistry, Medicinal

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

Amit A. Joharapurkar et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Chemistry, Organic

Combination of PhI(OAc)2 and 2-Nitropropane as the Source of Methyl Radical in Room-Temperature Metal-Free Oxidative Decarboxylation/Cyclization: Construction of 6-Methyl Phenanthridines and 1-Methyl Isoquinolines

Shi-Chao Lu et al.

JOURNAL OF ORGANIC CHEMISTRY (2018)

添加到收藏夹

Article Biochemical Research Methods

lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls

Daniel Eichner et al.

DRUG TESTING AND ANALYSIS (2017)

添加到收藏夹

Review Medicine, Research & Experimental

A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat

Kimberly Becker et al.

ADVANCES IN THERAPY (2017)

添加到收藏夹

Article Chemistry, Physical

Palladium Impurity Removal from Active Pharmaceutical Ingredient Process Streams A method for scale-up

Stephanie Phillips et al.

JOHNSON MATTHEY TECHNOLOGY REVIEW (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Synthesis of C3/C1-Substituted Tetrahydroisoquinolines

Mohamed Mihoubi et al.

MOLECULES (2015)

添加到收藏夹

Review Chemistry, Applied

Industrial Perspectives of Pharmaceutical Crystallization

Hsien-Hsin Tung

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2013)

添加到收藏夹

Editorial Material Chemistry, Applied

Innovation in Generic API Synthesis and Manufacture

Trevor Laird

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2012)

添加到收藏夹

Article Chemistry, Medicinal

Pharmaceutical Process Scale-Up, 3rd edition

Linda A. Felton

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2011)

添加到收藏夹

Article Chemistry, Analytical

Method for the Determination of Pd-Catalyst Residues in Active Pharmaceutical Ingredients by Means of High-Energy Polarized-Beam Energy Dispersive X-Ray Fluorescence

E. Margui et al.

ANALYTICAL CHEMISTRY (2009)

添加到收藏夹

Review Chemistry, Multidisciplinary

Hydrogen-bond-directed catalysis: Faster, regioselective and cleaner Heck arylation of electron-rich olefins in alcohols

Zeynab Hyder et al.

CHEMISTRY-A EUROPEAN JOURNAL (2008)

添加到收藏夹

Review Chemistry, Multidisciplinary

Aromaticity as a cornerstone of heterocyclic chemistry

AT Balaban et al.

CHEMICAL REVIEWS (2004)

添加到收藏夹

Review Biochemistry & Molecular Biology

The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses

CP Bracken et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2003)

添加到收藏夹

Article Chemistry, Organic

Palladium-catalyzed monoarylation of nitroalkanes

EM Vogl et al.

JOURNAL OF ORGANIC CHEMISTRY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.